- Home
- BDRX vs KZIA Comparison
BDRX vs KZIA Comparison
Compare BDRX & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- KZIA
- Stock Information
- Founded
- BDRX 2000
- KZIA 1994
- Country
- BDRX United Kingdom
- KZIA Australia
- Employees
- BDRX N/A
- KZIA N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- KZIA Health Care
- Exchange
- BDRX Nasdaq
- KZIA Nasdaq
- Market Cap
- BDRX 5.8M
- KZIA 5.1M
- IPO Year
- BDRX N/A
- KZIA 1999
- Fundamental
- Price
- BDRX $0.90
- KZIA $6.10
- Analyst Decision
- BDRX
- KZIA Strong Buy
- Analyst Count
- BDRX 0
- KZIA 2
- Target Price
- BDRX N/A
- KZIA $57.50
- AVG Volume (30 Days)
- BDRX 3.2M
- KZIA 2.6M
- Earning Date
- BDRX 04-11-2025
- KZIA 07-07-2025
- Dividend Yield
- BDRX N/A
- KZIA N/A
- EPS Growth
- BDRX N/A
- KZIA N/A
- EPS
- BDRX N/A
- KZIA N/A
- Revenue
- BDRX N/A
- KZIA $1,549,158.00
- Revenue This Year
- BDRX N/A
- KZIA N/A
- Revenue Next Year
- BDRX N/A
- KZIA N/A
- P/E Ratio
- BDRX N/A
- KZIA N/A
- Revenue Growth
- BDRX N/A
- KZIA 248983.08
- 52 Week Low
- BDRX $0.78
- KZIA $2.86
- 52 Week High
- BDRX $41.50
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- BDRX 39.25
- KZIA 50.96
- Support Level
- BDRX $0.85
- KZIA $5.83
- Resistance Level
- BDRX $0.97
- KZIA $9.60
- Average True Range (ATR)
- BDRX 0.11
- KZIA 1.19
- MACD
- BDRX -0.00
- KZIA -0.29
- Stochastic Oscillator
- BDRX 28.24
- KZIA 18.39
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.